JP2023513544A5 - - Google Patents
Info
- Publication number
- JP2023513544A5 JP2023513544A5 JP2022548194A JP2022548194A JP2023513544A5 JP 2023513544 A5 JP2023513544 A5 JP 2023513544A5 JP 2022548194 A JP2022548194 A JP 2022548194A JP 2022548194 A JP2022548194 A JP 2022548194A JP 2023513544 A5 JP2023513544 A5 JP 2023513544A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- alkenyl
- independently selected
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023132619A JP7443608B2 (ja) | 2020-02-07 | 2023-08-16 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| JP2024023916A JP7832243B2 (ja) | 2020-02-07 | 2024-02-20 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971825P | 2020-02-07 | 2020-02-07 | |
| US62/971,825 | 2020-02-07 | ||
| US202063016175P | 2020-04-27 | 2020-04-27 | |
| US63/016,175 | 2020-04-27 | ||
| US202063044330P | 2020-06-25 | 2020-06-25 | |
| US63/044,330 | 2020-06-25 | ||
| US202063063137P | 2020-08-07 | 2020-08-07 | |
| US63/063,137 | 2020-08-07 | ||
| PCT/US2021/016979 WO2021159040A2 (en) | 2020-02-07 | 2021-02-06 | Sars-cov-2 mrna domain vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132619A Division JP7443608B2 (ja) | 2020-02-07 | 2023-08-16 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513544A JP2023513544A (ja) | 2023-03-31 |
| JP2023513544A5 true JP2023513544A5 (https=) | 2023-08-24 |
| JP7438604B2 JP7438604B2 (ja) | 2024-02-27 |
Family
ID=74845093
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548194A Active JP7438604B2 (ja) | 2020-02-07 | 2021-02-06 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| JP2023132619A Active JP7443608B2 (ja) | 2020-02-07 | 2023-08-16 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| JP2024023916A Active JP7832243B2 (ja) | 2020-02-07 | 2024-02-20 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132619A Active JP7443608B2 (ja) | 2020-02-07 | 2023-08-16 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| JP2024023916A Active JP7832243B2 (ja) | 2020-02-07 | 2024-02-20 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230346914A1 (https=) |
| EP (1) | EP4100052A2 (https=) |
| JP (3) | JP7438604B2 (https=) |
| KR (1) | KR20220140528A (https=) |
| CN (1) | CN115551545A (https=) |
| AU (1) | AU2021215938A1 (https=) |
| BR (1) | BR112022015565A2 (https=) |
| CA (1) | CA3170150A1 (https=) |
| IL (1) | IL295377A (https=) |
| MX (1) | MX2022009707A (https=) |
| WO (1) | WO2021159040A2 (https=) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| CN113684219B (zh) * | 2020-05-18 | 2022-12-23 | 康希诺(上海)生物科技有限公司 | mRNA或mRNA组合物及其制备方法和应用 |
| CA3183735A1 (en) * | 2020-06-26 | 2021-12-30 | Martin P. STEINBUCK | Compositions and methods for inducing an immune response against coronavirus |
| WO2022046583A1 (en) * | 2020-08-24 | 2022-03-03 | Phylex Biosciences, Inc. | Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
| CN113980140B (zh) * | 2020-10-23 | 2024-06-25 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 融合蛋白及其应用 |
| CN114517205A (zh) * | 2020-11-20 | 2022-05-20 | 北京震旦鼎泰生物科技有限公司 | 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用 |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| WO2022155524A1 (en) * | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| US11524023B2 (en) * | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| JP2024511346A (ja) * | 2021-03-15 | 2024-03-13 | モデルナティエックス インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２ ｍｒｎａドメインワクチンの治療的使用 |
| DK4319803T3 (da) | 2021-04-08 | 2025-12-15 | Vaxthera Sas | Coronavirusvaccine omfattende et mosaikprotein |
| AU2022271249A1 (en) | 2021-05-04 | 2023-11-16 | BioNTech SE | Immunogen selection |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| WO2023022954A1 (en) * | 2021-08-15 | 2023-02-23 | Burton Dennis R | Undirected mutated mrna vaccine |
| AU2022330710A1 (en) * | 2021-08-17 | 2024-01-18 | Monash University | Vaccine compositions |
| US20250127880A1 (en) * | 2021-08-24 | 2025-04-24 | Victoria Link Limited | Fusion polypeptide |
| WO2023034991A1 (en) * | 2021-09-02 | 2023-03-09 | Kansas State University Research Foundation | Mrna vaccine formulations and methods of using the same |
| CN113527522B (zh) * | 2021-09-13 | 2021-12-21 | 深圳市瑞吉生物科技有限公司 | 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗 |
| CN116064598B (zh) * | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
| WO2023060483A1 (zh) * | 2021-10-13 | 2023-04-20 | 清华大学 | 多肽-rbd免疫偶联物及其用途 |
| WO2023064993A1 (en) * | 2021-10-21 | 2023-04-27 | The University Of Melbourne | Chimeric betacoronavirus spike polypeptides |
| EP4419136A1 (en) | 2021-10-21 | 2024-08-28 | BioNTech SE | Coronavirus vaccine |
| WO2023092069A1 (en) * | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| EP4436984A1 (en) * | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| AU2022398292A1 (en) | 2021-11-29 | 2024-06-13 | BioNTech SE | Coronavirus vaccine |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| IL288634A (en) * | 2021-12-02 | 2023-07-01 | Yeda Res & Dev | Improving the translation and protein secretion efficiency of mRNA vaccines |
| WO2023113094A1 (ko) * | 2021-12-16 | 2023-06-22 | 주식회사 씨티씨백 | 면역원성이 증가된 코로나바이러스감염증-19 백신 조성물 |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| CN116376942A (zh) * | 2021-12-31 | 2023-07-04 | 广州国家实验室 | mRNA疫苗 |
| CN114729373B (zh) * | 2022-01-27 | 2023-01-31 | 深圳市瑞吉生物科技有限公司 | 一种新型冠状病毒mRNA疫苗及其制备方法与应用 |
| WO2023142283A1 (zh) | 2022-01-27 | 2023-08-03 | 深圳市瑞吉生物科技有限公司 | 一种新型冠状病毒mRNA疫苗及其制备方法与应用 |
| CN116554042A (zh) * | 2022-01-30 | 2023-08-08 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
| WO2023143600A1 (zh) * | 2022-01-30 | 2023-08-03 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
| CN114213509B (zh) * | 2022-02-22 | 2022-06-10 | 广州市锐博生物科技有限公司 | 基于SARS-CoV-2的S蛋白的疫苗及其用途 |
| CN116726162A (zh) * | 2022-03-11 | 2023-09-12 | 病毒与疫苗研究中心有限公司 | 用于呼吸道病毒性疾病的疫苗加强组合物 |
| KR102850225B1 (ko) * | 2022-04-07 | 2025-09-18 | 엠큐렉스 주식회사 | 사스-코로나바이러스 2 감염증에 대한 rna 백신 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024086575A1 (en) | 2022-10-17 | 2024-04-25 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| CN115960923A (zh) * | 2022-11-24 | 2023-04-14 | 威瑞生物科技(昆明)有限责任公司 | 一种包含非人种属调控元件的SARS-COV-2刺突蛋白mRNA及其构建方法与应用 |
| CN120435314A (zh) * | 2022-12-29 | 2025-08-05 | 波普瓦克斯私人有限公司 | 多靶疫苗和治疗剂 |
| WO2024141784A2 (en) * | 2022-12-29 | 2024-07-04 | Popvax Private Limited | Broadly protective betacoronavirus vaccines and compositions |
| CR20250341A (es) * | 2023-01-20 | 2025-09-10 | Astrazeneca Ab | Moléculas de ácido nucleico |
| CN117003835A (zh) * | 2023-03-17 | 2023-11-07 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2奥密克戎突变株XBB及其亚型感染的蛋白及疫苗 |
| WO2025027492A1 (en) * | 2023-07-31 | 2025-02-06 | Pfizer Inc. | Coronavirus antigen variants |
| FR3155424A1 (fr) * | 2023-11-15 | 2025-05-23 | BioNTech SE | Compositions immunogènes contre le sars-cov-2 |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| WO2026047603A1 (en) * | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10121252A1 (de) | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2010531640A (ja) | 2007-06-29 | 2010-09-30 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 毒性化合物の分解方法 |
| CA2715078C (en) | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| SG10201408162PA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| CA2769670C (en) | 2009-07-31 | 2018-10-02 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| BR112015022855A2 (pt) | 2013-03-14 | 2017-11-07 | Shire Human Genetic Therapies | composições e método para produção de um anticorpo in vitro |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CA2942501A1 (en) * | 2014-03-17 | 2015-09-24 | Tapimmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
| PL4023249T3 (pl) * | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| WO2016138160A1 (en) * | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| JP6948313B6 (ja) * | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| US20190274968A1 (en) * | 2016-10-27 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| MA47515A (fr) * | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| EP3595676A4 (en) * | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| WO2019055807A1 (en) * | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US20230285539A1 (en) * | 2020-03-06 | 2023-09-14 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccines against sars-cov-2 and other coronaviruses |
-
2021
- 2021-02-06 BR BR112022015565A patent/BR112022015565A2/pt not_active Application Discontinuation
- 2021-02-06 US US17/797,784 patent/US20230346914A1/en active Pending
- 2021-02-06 AU AU2021215938A patent/AU2021215938A1/en not_active Abandoned
- 2021-02-06 MX MX2022009707A patent/MX2022009707A/es unknown
- 2021-02-06 CA CA3170150A patent/CA3170150A1/en active Pending
- 2021-02-06 EP EP21709270.9A patent/EP4100052A2/en active Pending
- 2021-02-06 KR KR1020227028371A patent/KR20220140528A/ko not_active Withdrawn
- 2021-02-06 IL IL295377A patent/IL295377A/en unknown
- 2021-02-06 WO PCT/US2021/016979 patent/WO2021159040A2/en not_active Ceased
- 2021-02-06 CN CN202180013506.4A patent/CN115551545A/zh active Pending
- 2021-02-06 JP JP2022548194A patent/JP7438604B2/ja active Active
-
2023
- 2023-08-16 JP JP2023132619A patent/JP7443608B2/ja active Active
-
2024
- 2024-02-20 JP JP2024023916A patent/JP7832243B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513544A5 (https=) | ||
| JP2024050973A5 (https=) | ||
| JP2023075344A5 (https=) | ||
| JP2024513999A5 (https=) | ||
| JP2022549171A5 (https=) | ||
| JP2023164537A5 (https=) | ||
| Jakob et al. | A novel approach to monodisperse, luminescent silica spheres | |
| JP2022501359A5 (https=) | ||
| RU2016137832A (ru) | Соединения для лечения опосредованных комплементом нарушений | |
| JP2022500543A5 (https=) | ||
| JP2010524939A5 (https=) | ||
| CN110642852B (zh) | 一种具有线粒体靶向的有机aie光敏探针及其制备方法和应用 | |
| JP2012526086A5 (https=) | ||
| RU2012142996A (ru) | Органосиликоны | |
| RU2012105467A (ru) | Триазолопиридиновое соединение и его действие в качестве ингибитора пролилгидроксилазы и индуктора выработки эритропоэтина | |
| JP2007508390A5 (https=) | ||
| JP2017515856A5 (https=) | ||
| JP2013529171A5 (https=) | ||
| JP2012513471A5 (https=) | ||
| RU2007111758A (ru) | Аминопроизводные 7- амино-3-фенилдигидропиримидо [4,5-d] пиримидинонов, их получение и применение в качестве ингибиторов протеинкиназ | |
| JP2014503001A5 (https=) | ||
| JP2003519068A5 (https=) | ||
| RU2015150120A (ru) | Соединение дикарбоновой кислоты | |
| JP2013523986A (ja) | 有機ケイ素ゾルの急速縮合によって得られるハイブリッド材料の製造方法 | |
| Mobinikhaledi et al. | Efficient synthesis of 2-amino-4H-chromene derivatives in the presence of piperazine-functionalized Fe3O4/SiO2 magnetic nanoparticles as a new heterogeneous reusable catalyst under solvent-free conditions |